
CPRX
Catalyst Pharmaceuticals markets three approved drug products: FIRDAPSE and AGAMREE (which appear to be newer focus areas), along with FYCOMPA. The firm operates as a commercial-stage biotech company focused on selling these marketed drugs while managing patent litigation and maintaining regulatory compliance. Current priorities include generating profitable, cash-flow positive operations from existing product sales rather than advancing drugs through clinical development.